Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: A Phase 2 RELEVANT-HCC Trial

NCT07514429 is registered in ClinicalTrials.gov with Ju Hyun Shim as lead sponsor.

NCT NCT07514429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07514429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: A Phase 2 RELEVANT-HCC Trial
Lead sponsor
Ju Hyun Shim
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 15, 2026
Completion date
June 30, 2028
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular, lenvatinib, treatment failure